Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $178.3 million.

  • Tg Therapeutics' Cash & Equivalents fell 8.95% to $178.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $178.3 million, marking a year-over-year decrease of 8.95%. This contributed to the annual value of $179.9 million for FY2024, which is 93.57% up from last year.
  • Latest data reveals that Tg Therapeutics reported Cash & Equivalents of $178.3 million as of Q3 2025, which was down 36.07% from $278.9 million recorded in Q2 2025.
  • Tg Therapeutics' Cash & Equivalents' 5-year high stood at $471.5 million during Q1 2021, with a 5-year trough of $61.5 million in Q1 2023.
  • In the last 3 years, Tg Therapeutics' Cash & Equivalents had a median value of $150.9 million in 2023 and averaged $151.8 million.
  • In the last 5 years, Tg Therapeutics' Cash & Equivalents soared by 805.87% in 2021 and then plummeted by 66.89% in 2023.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Cash & Equivalents stood at $298.9 million in 2021, then slumped by 65.77% to $102.3 million in 2022, then fell by 9.16% to $92.9 million in 2023, then surged by 93.57% to $179.9 million in 2024, then decreased by 8.95% to $178.3 million in 2025.
  • Its Cash & Equivalents was $178.3 million in Q3 2025, compared to $278.9 million in Q2 2025 and $276.2 million in Q1 2025.